NeuroMolecular Medicine

, Volume 5, Issue 2, pp 119–131

Matrix metalloproteinase-9 is elevated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice

Authors

  • Stefan Lorenzl
    • Department of Neurology and NeuroscienceWeill Medical College of Cornell University
  • Noel Calingasan
    • Department of Neurology and NeuroscienceWeill Medical College of Cornell University
  • Lichuan Yang
    • Department of Neurology and NeuroscienceWeill Medical College of Cornell University
  • David S. Albers
    • Department of Neurology and NeuroscienceWeill Medical College of Cornell University
  • Shuei Shugama
    • Burke Medical Research Institute
  • Jason Gregorio
    • Department of Neurology and NeuroscienceWeill Medical College of Cornell University
  • H. W. Krell
    • Pharmaceutical ResearchRoche Diagnostics GmbH
  • Jason Chirichigno
    • Department of Neurology and NeuroscienceWeill Medical College of Cornell University
  • Tong Joh
    • Burke Medical Research Institute
    • Department of Neurology and NeuroscienceWeill Medical College of Cornell University
Original Article

DOI: 10.1385/NMM:5:2:119

Cite this article as:
Lorenzl, S., Calingasan, N., Yang, L. et al. Neuromol Med (2004) 5: 119. doi:10.1385/NMM:5:2:119

Abstract

Matrix metalloproteinases (MMPs) are proteolytic enzymes capable of degrading components of the extracellular matrix. Recent evidence has implicated MMPs in the pathogenesis of neurodegenerative diseases as Alzheimer’s disease and amyotrophic lateral sclerosis. In this study, we investigated the involvement of MMP-9 (gelatinase B) in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson’s disease using zymography, immunohistochemistry, and Western blot analysis. The activity of MMP-9 was upregulated at 3 h after MPTP injection in the striatum and after 24 h in the substantia nigra. Although MMP-9 expression decreased in the striatum by 72 h, it remained elevated in the substantia nigra compared to controls up to 7 d after MPTP administration. Immunohistochemistry showed that neurons and microglia are the source of MMP-9 expression after MPTP administration to mice. Treatment with a hydroxamate-based MMP inhibitor, Ro 28-2653 significantly reduced dopamine depletion and loss of tyrosine hydroxylase immunoreactive neurons in the substantia nigra pars compacta. MMP-9 expression as measured via zymography in the substantia nigra was reduced by the MMP inhibitor. These results indicate that MMP-9 is induced after MPTP application in mice and that pharmacologic inhibition of MMPs protects against MPTP neurotoxicity.

Index Entries

Matrix metalloproteinaseszymographyMPTPParkinson’s disease

Copyright information

© Humana Press Inc 2004